Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AGEN
stocks logo

AGEN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
65.64M
+144.6%
0.660
-132.35%
30.20M
+25.49%
-0.560
-45.63%
30.20M
+17.51%
-0.580
-42%
Estimates Revision
The market is revising Downward the revenue expectations for Agenus Inc. (AGEN) for FY2025, with the revenue forecasts being adjusted by -22.17% over the past three months. During the same period, the stock price has changed by -6.24%.
Revenue Estimates for FY2025
Revise Downward
down Image
-22.17%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-124.27%
In Past 3 Month
Stock Price
Go Down
down Image
-6.24%
In Past 3 Month
Wall Street analysts forecast AGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGEN is 23.00 USD with a low forecast of 23.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast AGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGEN is 23.00 USD with a low forecast of 23.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.060
sliders
Low
23.00
Averages
23.00
High
23.00
Current: 4.060
sliders
Low
23.00
Averages
23.00
High
23.00
H.C. Wainwright
H.C. Wainwright
Neutral -> Buy
upgrade
$25
2025-06-04
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$25
2025-06-04
upgrade
Neutral -> Buy
Reason
H.C. Wainwright upgraded Agenus to Buy from Neutral with a $25 price target after the company entered into a strategic collaboration with Indian multinational pharmaceutical company Zydus Lifesciences. The definitive partnership is valued at up to $141M and is aimed at accelerating the clinical development of botensilimab and balstilimab while also securing scaled manufacturing both domestically and outside the U.S., the analyst tells investors in a research note. Th firm says that given Agenus' commitment to reducing its cash burn and the capital provided from this partnership, it now believes the company has sufficient funding to advance botensilimab and balstilimab through a Phase 3 trial initiating in the second half of 2025.
Baird
Baird
Neutral
maintain
$4 -> $6
2025-06-04
Reason
Baird
Baird
Price Target
$4 -> $6
2025-06-04
maintain
Neutral
Reason
Baird raised the firm's price target on Agenus to $6 from $4 and keeps a Neutral rating on the shares. The firm updatedits model following the receipt of ts $91M upfront payment from its strategic collaboration with Zydus.
Baird
Neutral
maintain
$3 -> $4
2025-05-13
Reason
Baird
Price Target
$3 -> $4
2025-05-13
maintain
Neutral
Reason
Baird raised the firm's price target on Agenus to $4 from $3 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results where the cmpoany is evaluating multiple proposals which are expected to bring in capital.
HC Wainwright & Co.
Emily Bodnar
Hold
Reiterates
n/a
2025-03-18
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
n/a
2025-03-18
Reiterates
Hold
Reason
HC Wainwright & Co.
Emily Bodnar
Hold
Reiterates
n/a
2025-03-12
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
n/a
2025-03-12
Reiterates
Hold
Reason
Baird
Colleen Kusy
Hold
Maintains
$6 → $3
2025-03-12
Reason
Baird
Colleen Kusy
Price Target
$6 → $3
2025-03-12
Maintains
Hold
Reason
Baird lowered the firm's price target on Agenus to $3 from $6 and keeps a Neutral rating on the shares. The firm updated its model following Q4 results and looks to focus on operational efficiency.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Agenus Inc (AGEN.O) is -6.06, compared to its 5-year average forward P/E of -5.55. For a more detailed relative valuation and DCF analysis to assess Agenus Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.55
Current PE
-6.06
Overvalued PE
18.54
Undervalued PE
-29.64

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.67
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.70
Undervalued EV/EBITDA
-2.04

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.01
Current PS
0.00
Overvalued PS
10.28
Undervalued PS
-0.26
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

AGEN News & Events

Events Timeline

(ET)
2025-11-18
09:34:08
Agenus names Jose Iglesias as Chief Medical Affairs Officer
select
2025-11-10 (ET)
2025-11-10
08:03:06
Agenus Announces Q3 Earnings Per Share of $1.94, Below Consensus Estimate of $2.20
select
2025-10-17 (ET)
2025-10-17
08:09:17
Agenus Reveals New Findings from its BOT/BAL at ESMO 2025
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
11-18Newsfilter
Agenus Names Dr. José Iglesias as Chief Medical Affairs Officer to Lead Global Medical Affairs and Early-Access Initiatives, Including France's AAC

  • Appointment of Dr. José Iglesias: Agenus has appointed Dr. José Iglesias as Chief Medical Affairs Officer, effective November 10, 2025, to lead global medical affairs for the immuno-oncology drugs botensilimab (BOT) and balstilimab (BAL) as they progress through Phase 3 evaluation and early-access programs.

  • Focus on MSS Colorectal Cancer: The BOT/BAL combination is being investigated for patients with microsatellite-stable colorectal cancer (MSS CRC), a group that has historically seen limited benefits from immunotherapy, highlighting the urgent need for effective treatment options.

  • Dr. Iglesias' Experience: Dr. Iglesias brings over 30 years of experience in oncology and immuno-oncology drug development, having previously held senior roles at various biopharmaceutical companies, and will focus on evidence generation and collaboration with healthcare professionals.

  • Agenus' Commitment to Patient Access: Agenus is dedicated to making investigational medicines available to cancer patients through appropriate early-access frameworks, including France's AAC program, ensuring responsible use and robust data collection.

[object Object]
Preview
9.5
11-11NASDAQ.COM
Agenus Stock Jumps 8.67% Following Q3 Results and Clinical Achievements

  • Stock Performance: Agenus Inc. (AGEN) shares increased by 8.67% to $4.3250 following the release of its third-quarter 2025 results and significant clinical and regulatory updates.

  • Regulatory Approval: France has approved reimbursed access for Agenus' BOT/BAL therapy in MSS mCRC, and a global Phase 3 trial (BATTMAN) is scheduled to begin in Q4 2025 at over 100 sites.

  • Trading Activity: The announcement led to unusually high trading volume for AGEN, indicating strong investor interest in the news.

  • Stock Range: The stock's 52-week price range is between $1.14 and $4.50, reflecting its volatility and market performance.

[object Object]
Preview
9.5
11-10Newsfilter
Agenus Announces Q3 2025 Results Highlighting Progress in Clinical and Regulatory Areas

  • Reimbursed Access in France: France's medicines agency has authorized reimbursed compassionate access for the immunotherapy combination of botensilimab and balstilimab (BOT/BAL) for patients with refractory MSS mCRC without active liver metastases, marking a significant step in patient access to innovative treatments.

  • Survival Data Presentation: New survival data presented at ESMO shows that BOT/BAL achieved a 42% two-year overall survival rate in heavily pretreated MSS mCRC patients and a 39% two-year overall survival across more than five refractory cancer types, indicating its potential effectiveness.

  • Phase 3 Trial Initiation: The global Phase 3 BATTMAN trial is set to commence in Q4 2025, evaluating BOT/BAL against best supportive care in patients with refractory, unresectable MSS/pMMR colorectal cancer across over 100 sites in multiple countries.

  • Financial Highlights and Future Plans: Agenus reported a net income of $63.9 million for Q3 2025, driven by a gain from the deconsolidation of MiNK, and plans to initiate patient enrollment for the BATTMAN trial by the end of 2025, alongside ongoing access programs in Europe.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Agenus Inc (AGEN) stock price today?

The current price of AGEN is 4.06 USD — it has decreased -2.64 % in the last trading day.

arrow icon

What is Agenus Inc (AGEN)'s business?

Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

arrow icon

What is the price predicton of AGEN Stock?

Wall Street analysts forecast AGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGEN is 23.00 USD with a low forecast of 23.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Agenus Inc (AGEN)'s revenue for the last quarter?

Agenus Inc revenue for the last quarter amounts to 30.24M USD, increased 20.40 % YoY.

arrow icon

What is Agenus Inc (AGEN)'s earnings per share (EPS) for the last quarter?

Agenus Inc. EPS for the last quarter amounts to 1.94 USD, decreased -162.99 % YoY.

arrow icon

What changes have occurred in the market's expectations for Agenus Inc (AGEN)'s fundamentals?

The market is revising Downward the revenue expectations for Agenus Inc. (AGEN) for FY2025, with the revenue forecasts being adjusted by -22.17% over the past three months. During the same period, the stock price has changed by -6.24%.
arrow icon

How many employees does Agenus Inc (AGEN). have?

Agenus Inc (AGEN) has 316 emplpoyees as of December 05 2025.

arrow icon

What is Agenus Inc (AGEN) market cap?

Today AGEN has the market capitalization of 138.07M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free